Picture of Veritas in Silico logo

130A Veritas in Silico Share Price

0.000.00%
jp flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-36.88%
3m-42.64%
6mn/a
1yrn/a
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-66.85%
50d MA-25.25%
200d MA-36.4%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value3.17
Price to Tang. Book3.17
Price to Free Cashflow112.08
Price to Sales19.04
EV to EBITDA1,578.51

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-1.16%
Return on Equity-2.81%
Operating Margin-6.98%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Veritas in Silico EPS forecast chart

Profile Summary

Veritas In Silico Inc is a Japan-based company primarily engaged in the pharmaceutical discovery platform business. The main business is small molecule drug discovery targeting messenger ribonucleic acid (mRNA) using the ibVIS platform, which integrates digital technology including in silico ribonucleic acid (RNA) structural analysis technology and drug discovery technology, through joint drug discovery research with pharmaceutical companies to create mRNA-targeted small molecule drugs.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    March 31st, 2024
    Incorporated
    November 17th, 2016
    Public Since
    February 8th, 2024
    No. of Employees
    15
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    jp flag iconTokyo Stock Exchange
    Shares in Issue
    6,487,114

    130A Share Price Performance

    Upcoming Events for 130A

    Dividend For 130A.T - 0.0000 JPY

    Similar to 130A

    Picture of 3-D Matrix logo

    3-D Matrix

    jp flag iconTokyo Stock Exchange

    Picture of AnGes logo

    AnGes

    jp flag iconTokyo Stock Exchange

    Picture of BrightPath Biotherapeutics Co logo

    BrightPath Biotherapeutics Co

    jp flag iconTokyo Stock Exchange

    Picture of Carna Biosciences logo

    Carna Biosciences

    jp flag iconTokyo Stock Exchange

    Picture of Chiome Bioscience logo

    Chiome Bioscience

    jp flag iconTokyo Stock Exchange

    FAQ